New nanoparticle COVID vaccine aims to outsmart future variants

NCT ID NCT07183709

Ongoing ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 31 times

Summary

This early-stage study tests a new COVID-19 booster vaccine called PepGNP-COVID19 in 60 healthy adults aged 18-64. Unlike current vaccines, it uses tiny gold particles to train the body's T-cells to recognize and attack the virus, potentially providing broader and longer-lasting protection. The main goal is to check safety and find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID - 19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cincinnati Children's Hospital Medical Center Vaccine Research Center

Cincinnati, Ohio, 45229, United States
George Washington University Medical Faculty Associates

Washington D.C., District of Columbia, 20037-3201, United States
University of Alabama at Birmingham School of Medicine - Infectious Disease

Birmingham, Alabama, 35222, United States

Conditions

Explore the condition pages connected to this study.

COVID - 19